Specificity exchangers that redirect antibodies to bacterial...

Details Specificity exchangers that redirect antibodies to bacterial... Specificity exchangers that redirect antibodies to bacterial...

2005-08-23

2005-08-23

Stucker, Jeffrey (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000

Reexamination Certificate

active

06933366

ABSTRACT:
Specificity exchangers and methods of making and using specificity exchangers are disclosed. Specificity exchangers are useful for preventing and treating human diseases including cancer and those resulting from pathogens such as bacteria, yeast, parasites, fungus, viruses, and the like. More specifically, specificity exchangers can redirect existing antibodies in a subject to pathogens and cancer cells.

REFERENCES:
patent: 4169138 (1979-09-01), Jonsson
patent: 4376110 (1983-03-01), David et al.
patent: 4471058 (1984-09-01), Smith et al.
patent: 4486530 (1984-12-01), David et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5175096 (1992-12-01), Hook et al.
patent: 5189015 (1993-02-01), Hook et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5260189 (1993-11-01), Formoso et al.
patent: 5320951 (1994-06-01), Hook et al.
patent: 5416021 (1995-05-01), Hook et al.
patent: 5440014 (1995-08-01), Hook et al.
patent: 5561049 (1996-10-01), Vold et al.
patent: 5571511 (1996-11-01), Fischer
patent: 5571514 (1996-11-01), Hook et al.
patent: 5582975 (1996-12-01), Milliman
patent: 5601830 (1997-02-01), Su et al.
patent: 5627263 (1997-05-01), Ruoslahti et al.
patent: 5652217 (1997-07-01), Hook et al.
patent: 5700928 (1997-12-01), Hodgson et al.
patent: 5766857 (1998-06-01), Ruoslahti et al.
patent: 5766951 (1998-06-01), Brown
patent: 5770208 (1998-06-01), Fattom et al.
patent: 5770702 (1998-06-01), Hook et al.
patent: 5776712 (1998-07-01), Kuusela et al.
patent: 5789549 (1998-08-01), Hook et al.
patent: 5840846 (1998-11-01), Hook et al.
patent: 5843774 (1998-12-01), Ginsberg
patent: 5846536 (1998-12-01), Bissell et al.
patent: 5866541 (1999-02-01), Hook et al.
patent: 5869232 (1999-02-01), Sallberg
patent: 5888738 (1999-03-01), Hendry
patent: 5929220 (1999-07-01), Tong et al.
patent: 5939273 (1999-08-01), Lussow et al.
patent: 5942606 (1999-08-01), Lal et al.
patent: 5955078 (1999-09-01), Burnham et al.
patent: 5980908 (1999-11-01), Hook et al.
patent: 5981274 (1999-11-01), Tyrell et al.
patent: 6008341 (1999-12-01), Foster et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6040137 (2000-03-01), Sallberg
patent: 6066648 (2000-05-01), Duggan et al.
patent: 6077677 (2000-06-01), Hodgson et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6086895 (2000-07-01), Hook et al.
patent: 6087330 (2000-07-01), Kogan et al.
patent: 6090388 (2000-07-01), Wang
patent: 6090944 (2000-07-01), Hutchinson
patent: 6093539 (2000-07-01), Maddon et al.
patent: 6245985 (2001-06-01), Sasaki et al.
patent: 6417324 (2002-07-01), Sällberg
patent: 6469143 (2002-10-01), Sallberg
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 6660842 (2003-12-01), Sallberg
patent: 2002/0025513 (2002-02-01), Sällberg
patent: 2002/0058247 (2002-05-01), Sällberg
patent: 2003/0021789 (2003-01-01), Xu et al.
patent: 2003/0044418 (2003-03-01), Davis et al.
patent: 0 182 546 (1986-05-01), None
patent: 0 508 427 (1992-10-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 93/17044 (1993-09-01), None
patent: WO 94/13804 (1994-06-01), None
patent: WO 95/08577 (1995-03-01), None
patent: WO 95 29938 (1995-11-01), None
patent: WO 95/29938 (1995-11-01), None
patent: WO 98/03543 (1998-01-01), None
patent: WO 98/31389 (1998-07-01), None
patent: WO 98/43677 (1998-10-01), None
patent: WO 99/27109 (1999-06-01), None
patent: WO 99 61041 (1999-12-01), None
patent: WO 00 26385 (2000-05-01), None
patent: WO 95 22249 (2000-05-01), None
patent: WO 00/66621 (2000-11-01), None
patent: WO 01/82546 (2001-01-01), None
patent: WO 01/81421 (2001-11-01), None
patent: WO 02/24887 (2002-03-01), None
Leibiger et al. (1998) Structural characterization of the oligosaccharides of a human monoclonal anti-lipopolyssaccharide immunoglobulin M. Glycobiology. 8(5):497-507.
Lin et al. (1998) Differential recognition by proteins of α-galactosyl residues on endothelial cell surfaces. Glycobiology. 8(5):433-443.
Mizukami et al. (1988) Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis. Proc. Natl. Acad. Sci. 85:9273-9277.
E. Bianchi et al., “The Making of the Minibody: An Engineered Beta-Proten for the Display of Conformationally Constrained Peptides,”Journal of Molecular Recognition,7(1):9-24 (1994).
Database Genseq 'Online! Oct. 21, 1991, Asahi Chemical Ind. KK: “L-chain variable region of plasminogen activator antibody” XP002183673, Accession AAP61027 (published in JP11729000).
Database Genseq 'Online! Jan. 8, 1993, Clonatec SA: “Hepatitis B irus HBc antigen II,” XP002183674, Accession AAR25272 (published in EP494825).
Database Genseq 'Online! Jul. 1, 1993, Cytel Corp: “Cytotoxic T-lymphocyte inducing peptide 802.03.” XP002183675, Accession AAR33488.
Database WPI, Section Ch., Week 199713, Derwent Publications Ltd., London, GB: Class B04, AN 1997-140911, XP002183678 & JP 09 020798 A (Asahi Kasei Kogyo KK) Jan. 21, 1997, abstract.
Database Patent_PRT 'Online! Mar. 21, 2001, Eurodiagnostica AB: “Sequence 9 from Patent W)0116163” XP002183677, Accession AX 090806.
Database Genseq 'Online! Jul. 31, 2000, Yeda Res & Dev Co Ltd: “Murine anti-Pab-421 IDI-1 mAb heavy chain CDR based Peptide IDI-H1”, XP002183676, Accession AAY70799 (published in WO0023082).
Ganem, “Hepadnaviridae and their replication,”Fields Virology,Third Ed., pp. 2703-2705 (1996).
GenCore Sequence Alignment of Sequence ID No: 16 with the L-chain variable region of plasminogen activator antibody of JP61172900-A, Ashi Chemical Ind. KK. (Apr. 8, 1986) ID No: p. 61027.
Grabowska et al., “Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1,”Journal of General Virology,80(pt.7):1789-1798 (1999).
Greenspan et al., Nature Biotechnology, 7:936-937 (1999).
Korba and Gerin, “Generation of a large combinatorial library of immunoglobulin repertoire in Phage Lambda,” Science, 256:1275-1281 (1989).
Korba and Milman, “A cell culture assay for compounds which inhibit hepatitis B virus repolication,” Antiviral Res, 15(3):217-228 (1991).
Lazdina et al., Journal of Virology, 75(14):6367-6374 (2001).
Machida et al., “Antigenic sites on the arginine-rich carboxyl-terminal doman of the capsid protein of hepatitis B virus distinct form hepatitis B core or e antigen,” Mol. Immunol. 26(4):421-431 (1989).
McDevvit et al., “Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) ofStaphylococcus aureus,” Molecular Microbiology, vol. 16, No. 5, pp. 895-907 (1995).
Milich et al., “The humoral immune response in acute and chronic hepatitis B virus infection,”Springer Semin. Immunopathol.,17:149-166 (1995).
Milich et al, “The Nucleocapsid of Hepatitis B Virus is both a T-Cell-Independent Antigen,”Science,234:1398-1401 (1986).
Milich et al., “Role of B cells in antigen presentation of the hepatitis B core,”Proc. Natl. Acad. Sci. USA,94:14648-14653 (1997).
Prange et al., Journal of Biological Chemistry, 380(3):305-314 (1999).
Salfeld et al., “Antigenic determinants an dfunctional domains in core antigen and e antigen from hepatitis B virus,” Journal of Virology, 63(2):798-808 (1989).
Sallberg et al., “Characterization of a linear binding site for a monoclonal antibody to hepatitis B core antigen,” J. Med. Virol., 33(4):248-252 (1991).
Sallberg et al., “Immunochemical structure of the carboxy-terminal part of hepatitis B e antigen: identification of internal and surface-exposed sequences,”Journal of General Virology,74:1335-1340 (1993).
Sallberg et al., “Human and murine B-cells recognize the HBeAg/beta (or HBe2) epitope as a lin

Affiliated with

Also associated with

Rating

Specificity exchangers that redirect antibodies to bacterial... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Specificity exchangers that redirect antibodies to bacterial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specificity exchangers that redirect antibodies to bacterial... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3495413